Gary Glick, PhD

Dr. Gary Glick serves as a Scientific Advisor to Aktis Oncology. He is a chemist and serial biotech entrepreneur with over 15 years’ experience in the biotech industry, currently serving as Founder, President, and Chief Executive Officer of Odyssey Therapeutics. Prior to Odyssey, Dr. Glick founded several successful companies, including IFM Therapeutics. While Dr. Glick was CEO of IFM, the company progressed three programs from ideation to clinical development and executed several major transactions, including the sale of oncology assets to Bristol Myers Squibb in a transaction valued at more than $2.3 billion, and the sale of an NLRP3 inhibitor program to Novartis for $1.6 billion. Prior to Odyssey in 2020, he co-founded and launched Scorpion Therapeutics, where he played an instrumental role in the conception and building of the company. During his tenure as CEO, Scorpion grew to nearly 50 employees and raised $270 million across two financings. Dr. Glick received his Ph.D. in organic chemistry from Columbia University and completed an NIH postdoctoral fellowship in organic chemistry at Harvard University. He is the author of more than 100 papers, the inventor on 54 issued U.S. patents, and the recipient of numerous awards recognizing his scientific contributions and accomplishments as a life sciences executive.